Clinical trials: Patient Derived Organoid
Esophageal Cancer
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Study Title: Observing Clinical Consistency of Personalized Neoadjuvant Therapy Using Patient-Derived Organoid Models (PDO) in Resectable Esophageal Squamous Cell Carcinoma Goal: This study aims to explore whether patient-derived…
- Trial name
- NCT07054086
- Testing
- Neoadjuvant Chemotherapy (NACT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Cancer, Organoid
Patient-derived Organoids of Lung Cancer to Test Drug Response
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO)…
- Trial name
- NCT03979170
- Testing
- Lung tumor resection
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Geneva
Meningioma
Establishment and Characterization of Meningioma Patient-derived Organoids
In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.
- Trial name
- NCT04478877
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Breast Cancer, Breast Cancer (Triple Negative Type)
Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded…
- Trial name
- SENOCOHORT (NCT07833891)
- Testing
- Patients follow-up
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma, Glioblastoma Multiforme (GBM)
Patient's Derived Organoids for Drug Screening in Glioblastoma
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention.
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme, Adult
- Trial name
- GlioPDO (NCT06781372)
- Testing
- Development and characterization of PDOs, Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Biliary Anastomosis Complication
Organoids for Bile Leaks
Background: Bile leakage remains a major complication after hepatobiliary surgery and liver transplantation. While most cases are managed through standard radiologic or endoscopic interventions, a subset of patients fails to…
- Trial name
- ASCORB (NCT07214649)
- Testing
- Organoid-guided treatment
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Gastric Carcinoma
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. However, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from the treatment.
- Trial name
- NCT05351398
- Testing
- PDO group, Traditional group
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
NSCLC
Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients
This clinical study aims to evaluate the feasibility to predict clinical response of target therapy or chemotherapy drugs based on the ex vivo drug sensitivity data using patient-derived organoids.
- Trial name
- NCT03453307
- Where
- China
- Volunteers
- 100 people
- Sponsor
- K2 Oncology, Inc.
Organoids, HNSCC
Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)
This is a single-centre study based on the Simon 2-stage optimax design: 12 patients will be enrolled initially (Stage I), which will then be expanded to a further 13 patients (Stage II) if 3 or more patients enrolled in stage I…
- Conditions
- Organoids, HNSCC, Epithelial Ovarian Cancer, Colorectal Cancer
- Trial name
- NCT04279509
- Testing
- Tumor Core Biopsy, Blood sampling
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National University Hospital, Singapore
Medulloblastoma
Targeting MYC in High-Risk Medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by…
- Trial name
- MYCMB (NCT07694622)
- Testing
- Tumor tissue collection
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Neoplasms
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients'…
- Trial name
- PDO (NCT06468124)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Organoid
Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 2 years. The purpose of this study is to evaluate the consistency and accuracy of Patient-Derived Organoid Model of…
- Trial name
- NCT03544047
- Testing
- Paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College
Gastric Cancer
Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer
Gastric cancer is the fourth leading cause of cancer-related death worldwide. Accurate assessment of the clinical responses to current treatment regimens is key to improving the prognosis and prolonging the survival of patients.
- Trial name
- NCT05203549
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China